IDEAYA Biosciences (IDYA) announced positive clinical data from its mid-stage study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat heavily pre-treated methylthioadenosine phosphorylase (MTAP)-deletion urothelial (bladder) and non-small cell lung cancer (NSCLC) patients. Shares of the company soared 15.3% on Jun 8 in response.Management believes that theIDE397 study data demonstrates important clinical proof-of-concept in MTAP-deletion solid tumors to deliver meaningful responses and enco ...